FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation